



QPS LLC
Delaware Technology Park
1 Innovation Way, Suite 200
Newark, DE 19711, USA

Email covid19study@qps.com.com
Tel +1 302 369 5601
Fax +1 302 369 5602

Good Day,

The global COVID-19 Pandemic affects every American and every American business. We all need to get back to work. If your organization has a plan to assess the infection status of its staff or if you have a process in place to perform contact tracing, QPS can help by providing the molecular test.

QPS, LLC has an FDA Emergency Use Authorized (EUA) COVID-19 molecular assay for detection of SARS-CoV-2 available as a private contract service in the USA.

Features of the service include:

1. Onsite sample collection by trained nurses
2. All necessary Personal Protective Equipment (PPE)
3. All necessary collection material
4. 48-hour results turnaround

Sample analysis is being done in our CLIA facility in Newark, Delaware. We meet all the regulatory requirements for regulated, high- complexity CLIA testing and can collect and process samples from all 50 States.

Please find attached a synopsis of the QPS testing capability and the current CDC guidance on Occupational Medicine Surveillance, then contact us for a consultation at Covid19study@qps.com.

Kind regards,
John L Kolman



John L Kolman, Ph.D.

Vice President, QPS LLC
Global Head, Translational Medicine, QPS Holdings, LLC
QPS LLC | Delaware Technology Park | 1 Innovation
Way | Suite 200 | Newark | DE 19711 | USA
Mob 302 763-2191 | Tel 302 369-5243
Email john.kolman@qps.com | Web www.qps.com

www.qps.com